Preview

Fundamental and Clinical Medicine

Advanced search

CLINICAL CASE OF OBSTETRIC ATYPICAL HEMOLYTIC UREMIC SYNDROME

Abstract

Here we present a clinical case of atypical hemolytic uremic syndrome (aHUS) associated with delivery. Even in timely diagnosed patients with aHUS, case fatality rate reaches 29%. Currently, aHUS is considered as a thrombotic microangiopathy, along with typical hemolytic uremic syndrome, thrombotic thrombocytopenic purpura, severe preeclampsia, and HELLP syndrome. There is a considerable genetic predisposition to all abovementioned types of thrombotic microangiopathy; however, additional significant stimulation of the complement system is mandatory for aHUS to occur. In children, it can be triggered by respiratory or gastrointestinal infections, while in women it is typically provoked by pregnancy. High mortality of aHUS is due to its rarity and consequent low awareness, non-specific symptoms at its initiation, and rapid development of multiple organ failure including acute kidney injury due to generalized thrombosis in the microvasculature. Successful treatment of aHUS largely depends on the timeliness of diagnosis, specific therapy with eculizumab in combination with a renal replacement therapy, and rapid delivery according to the protocol on severe pre-eclampsia.

About the Authors

SVETLANA CH. Kara-Sal
Tyva Republic Perinatal Center
Russian Federation


VADIM G. Mozes
Kemerovo State Medical University
Russian Federation


KIRA B. Mozes
Kemerovo State Medical University
Russian Federation


ELENA V. Rudaeva
Kemerovo State Medical University
Russian Federation


IGOR S. Zakharov
Kemerovo State Medical University
Russian Federation


SVETLANA I. Yelgina
Kemerovo State Medical University
Russian Federation


References

1. Nester CM, Thomas CP. Atypical hemolytic uremic syndrome: what is this, how is it diagnosed, and how is it treated? Hematology Am Soc Hematol Educ Program. 2012; 2012: 617-625. doi: 10.1182/asheducation-2012.1.617

2. Meri S. Complement activation in deseases presenting with thrombotic microangiopathy. Eur J Intern Med. 2013; 24 (6): 496-502. doi: 10.1016/j.ejim.2013.05.009

3. Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa M, Grinyó JM, et al. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2013; 33 (1): 27-45. doi: 10.3265/Nefrologia.pre2012.Nov.11781

4. Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical haemolytic uraemic syndrome. N Engl J Med. 2013; 368 (23): 2169-2181. doi: 10.1056/NEJMoa1208981


Review

For citations:


Kara-Sal S.Ch., Mozes V.G., Mozes K.B., Rudaeva E.V., Zakharov I.S., Yelgina S.I. CLINICAL CASE OF OBSTETRIC ATYPICAL HEMOLYTIC UREMIC SYNDROME. Fundamental and Clinical Medicine. 2019;4(1):91-99. (In Russ.)

Views: 463


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2500-0764 (Print)
ISSN 2542-0941 (Online)